Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of benzisoxazoles—aromatic compounds containing a benzene ring fused to an isoxazole ring. Its molecular formula is C19H20ClN3O4 and it has a molecular weight of approximately 389.8 Da[1][2][3][4][7]. The structure features both morpholine and phenolic groups. There are no known approved medical indications or clinical trials for this compound as of now; it appears in chemical databases as an experimental or research molecule with no established pharmacological mechanism or therapeutic use[1][9]. No information on its mechanism of action, biological targets, or clinical development status is available in public pharmaceutical resources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol.